Shin Nippon Biomedical Laboratories beats H1 forecasts, declares interim dividend

Shin Nippon Biomedical Laboratories (SNBL) announced that its consolidated financial results for the six months ended September 30, 2025, exceeded initial forecasts in both revenue and profit. Revenue reached 14,766 million yen, surpassing the forecast of 14,542 million yen. Operating profit reached 49 million yen, significantly outperforming the forecast of a 97 million yen loss. This improvement was largely due to steady performance of the CRO business, lower-than-projected losses at its US subsidiary Satsuma Pharmaceuticals, Inc. (1,386 million yen vs. 1,743 million yen forecast), and profitability in the Medipolis business.

SNBL declared an interim dividend of 20.00 yen per share from retained earnings for shareholders on record as of September 30, 2025, consistent with its initial plan. Total dividends amount to 832 million yen, with an effective date of November 28, 2025. This decision aligns with the company's policy of stable profit distributions and steady progress.

Despite a year-over-year decline in operating profit, attributed to a temporary negative accounting impact of 670 million yen for NHP imports, increased depreciation expenses of 420 million yen, and higher expenses at Satsuma of 110 million yen, all factors were within expectations and do not impact the full-year forecast. The company’s H1 revenue achieved a record high for the fourth consecutive year.